Market capitalization | $7.95m |
Enterprise Value | $7.67m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 17.84 |
P/S ratio (TTM) P/S ratio | 18.49 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 0.71% |
Revenue (TTM) Revenue | $430.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast BioCardia Inc.:
1 Analyst has issued a forecast BioCardia Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 0.43 0.43 |
0%
0%
|
|
Gross Profit | 0.01 0.01 |
50%
50%
|
|
EBITDA | -8.19 -8.19 |
35%
35%
|
EBIT (Operating Income) EBIT | -8.61 -8.61 |
34%
34%
|
Net Profit | -8.56 -8.56 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
Head office | United States |
CEO | Peter Altman |
Employees | 20 |
Founded | 1994 |
Website | www.biocardia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.